Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma
Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma
复制标题
DOI：
10.1016/j.heliyon.2019.e02004
复制
发表时间：
2019-07-01
期刊：
影响因子：
4
通讯作者：
Nakagawa, Takayuki
中科院分区：
文献类型：
--
作者：
Yoshimoto, Sho;Kato, Daiki;Nakagawa, Takayuki
人表皮生长因子受体2(HER2)在包括甲状腺癌(TC)在内的多种人类肿瘤中均有表达，可作为诊断标记物和治疗靶点。犬TC(CTC)是犬最常见的内分泌恶性肿瘤，具有较高的转移率，HER2靶向治疗可能是一种候选的治疗方法。在这里，我们用免疫组织化学方法检测了21例石蜡包埋的CTC组织中HER2的表达，并根据表达强度和阳性程度进行评分(评分：0-3+)。4个样本(19%)得3+；6个(29%)得2+；7个(33%)得1+；4个(19%)得0。因此，48%的CTC组织HER2阳性(Score>；=2+)。这些数据可能导致进一步评估HER2在CTC中作为恶性机制和治疗靶点的作用。
The human epidermal growth factor receptor 2 (HER2) is expressed in various human cancers including thyroid cancers (TC) and is used as a diagnostic marker and therapeutic target. Canine TC (cTC), the most common endocrine malignancy in dogs, shows a high metastasis rate, and HER2-targeted therapy could be a candidate for treatment. Here, we immunohistochemically evaluated HER2 expression in 21 paraffin-embedded cTC tissues and scored the degree of expression based on intensity and positivity (score: 0-3+). Four samples (19%) scored 3+; 6 (29%), 2+; 7 (33%), 1+; and 4 (19%), 0. Therefore, 48% of the cTC tissues were HER2 positive (scored >= 2+). These data may lead to further evaluation of the role of HER2 in cTC as a mechanism of malignancy and a therapeutic target.